FIGURE 5.

Wt EGFR and EGFR L393F bind Cetuximab only after they exit the ER. RBL-2H3 cells transiently expressing WT EGFR-GFP, EGFR-GFP L393F (LF), or EGFR-GFP L393H (LH) for either 12 h or 24 h were fixed, permeabilized, and labeled with the anti-EGFR mAb Cetuximab followed by Alexa 647-anti-mouse IgG to label the EGF binding segment of the expressed EGFR construct. Specific labeling was observed once the receptors exit the ER, and EGFR L393F bound Cetuximab as well as WT EGFR in both the Golgi region and PM. Scale bar, 10 μm.